Administration makes it easier for companies to profit from publicly funded virus drugs, group says

In its race to control covid-19, the U.S. government is spending billions in agreements with drugmakers to subsidize development of medicines. But it is using a looser standard of contracting that avoids some rules that protect taxpayer investments, Knowledge Ecology International said.